Kapila Ratnam, PhD
Dr. Ratnam is a Principal at NewSpring Capital, where her investment focus is on healthcare IT, pharmaceutical services, diagnostics and specialty pharmaceuticals (particularly, generics and post-approval products). Her prior experience is in drug discovery and development, as well as enabling biotechnologies. Her therapeutic domain knowledge, which spans several disease areas, was gained at pharmaceutical companies and contract research organizations.
Kapila has been a Board member/Board observer at Corridor Pharmaceuticals, Inc., Precyse LLC, RedPath Integrated Pathology, Inc. and Putney, Inc. and has played active roles in several other portfolio companies. She has a Ph.D. from the Ohio State University and completed her postdoctoral training at the University of Pennsylvania. Dr. Ratnam also has an MBA from Columbia University.